Hydrodynamic delivery of mIL10 gene protects mice from high-fat diet-induced obesity and glucose intolerance

Molecular Therapy

Volumn 21, Issue 10, 2013, Pages 1852-1861

  Gao, Mingming ^a   Zhang, Chunbo ^a   Ma, Yongjie ^a   Bu, Le ^a   Yan, Linna ^a   Liu, Dexi ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 10; PLASMID DNA;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; GENE; GENE OVEREXPRESSION; GFP GENE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYDRODYNAMICS BASED TRANSFECTION; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; LIPID DIET; MACROPHAGE; MALE; METABOLIC DISORDER; MIL10 GENE; MOUSE; NONHUMAN; OBESITY;

ANIMALIA; MUS;

ADIPOSE TISSUE; ANIMALS; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; GENETIC VECTORS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYDRODYNAMICS; INTERLEUKIN-10; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OBESITY; PLASMIDS; TRANSFECTION; WEIGHT GAIN;

EID: 84885020680     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.125     Document Type: Article

References (31)

1. Yanovski, SZ and Yanovski, JA (2011). Obesity prevalence in the United States-up, down, or sideways? N Engl J Med 364: 987-989.
2. http://www.cdc.gov/obesity/data/index.html.
3. Zimmet, P, Alberti, KG and Shaw, J (2001). Global and societal implications of the diabetes epidemic. Nature 414: 782-787.
4. Caprio, S, Daniels, SR, Drewnowski, A, Kaufman, FR, Palinkas, LA, Rosenbloom, AL et al. (2008). Influence of race, ethnicity, and culture on childhood obesity: implications for prevention and treatment: a consensus statement of Shaping America's Health and the Obesity Society. Diabetes Care 31: 2211-2221.
5. Dietrich, MO and Horvath, TL (2012). Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov 11: 675-691.
6. Pi-Sunyer, FX (2004). Pathophysiology and long-term management of the metabolic syndrome. Obes Res 12 (suppl.): 174S-180S.
7. Furukawa, S, Fujita, T, Shimabukuro, M, Iwaki, M, Yamada, Y, Nakajima, Y et al. (2004). Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761.
8. Monteiro, R and Azevedo, I (2010). Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010: pii: 289645.
9. Xu, H, Barnes, GT, Yang, Q, Tan, G, Yang, D, Chou, CJ et al. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830.
10. Asadullah, K, Sterry, W and Volk, HD (2003). Interleukin-10 therapy-review of a new approach. Pharmacol Rev 55: 241-269.
11. Juge-Aubry, CE, Somm, E, Pernin, A, Alizadeh, N, Giusti, V, Dayer, JM et al. (2005). Adipose tissue is a regulated source of interleukin-10. Cytokine 29: 270-274.
12. Bluher, M, Fasshauer, M, Tonjes, A, Kratzsch, J, Schon, MR and Paschke, R (2005). Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 113: 534-537.
13. Manigrasso, MR, Ferroni, P, Santilli, F, Taraborelli, T, Guagnano, MT, Michetti, N et al. (2005). Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab 90: 5876-5879.
14. Scarpelli, D, Cardellini, M, Andreozzi, F, Laratta, E, Hribal, ML, Marini, MA et al. (2006). Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes 55: 1529-1533.
15. Hong, EG, Ko, HJ, Cho, YR, Kim, HJ, Ma, Z, Yu, TY et al. (2009). Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 58: 2525-2535.
16. Ogura, M, Urabe, M, Akimoto, T, Onishi, A, Ito, C, Ito, T et al. (2012). Interleukin-10 expression induced by adeno-associated virus vector suppresses proteinuria in Zucker obese rats. Gene Ther 19: 476-482.
17. den Boer, MA, Voshol, PJ, Schroder-van der Elst, JP, Korsheninnikova, E, Ouwens, DM, Kuipers, F et al. (2006). Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology 147: 4553-4558.
18. Cintra, DE, Pauli, JR, Araujo, EP, Moraes, JC, de Souza, CT, Milanski, M et al. (2008). Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol 48: 628-637.
19. Morari, J, Torsoni, AS, Anhe, GF, Roman, EA, Cintra, DE, Ward, LS et al. (2010). The role of proliferator-activated receptor gamma coactivator-1alpha in the fatty-aciddependent transcriptional control of interleukin-10 in hepatic cells of rodents. Metab Clin Exp 59: 215-223.
20. Hashem, RM, Mahmoud, MF, El-Moselhy, MA and Soliman, HM (2008). Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis. Eur J Gastroenterol Hepatol 20: 995-1001.
21. Gotoh, K, Inoue, M, Shiraishi, K, Masaki, T, Chiba, S, Mitsutomi, K et al. (2012). Spleen-derived interleukin-10 downregulates the severity of high-fat diet-induced non-alcoholic fatty pancreas disease. PLoS ONE 7: e53154.
22. van Exel, E, Gussekloo, J, de Craen, AJ, Frolich, M, Bootsma-Van Der Wiel, A and Westendorp, RG; Leiden 85 Plus Study (2002). Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 51: 1088-1092.
23. Murano, I, Barbatelli, G, Parisani, V, Latini, C, Muzzonigro, G, Castellucci, M et al. (2008). Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 49: 1562-1568.
24. Shi, H, Kokoeva, MV, Inouye, K, Tzameli, I, Yin, H and Flier, JS (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116: 3015-3025.
25. Henao-Mejia, J, Elinav, E, Jin, C, Hao, L, Mehal, WZ, Strowig, T et al. (2012). Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185.
26. Stienstra, R, van Diepen, JA, Tack, CJ, Zaki, MH, van de Veerdonk, FL, Perera, D et al. (2011). Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 108: 15324-15329.
27. Liu, F, Song, Y and Liu, D (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6: 1258-1266.
28. Zhang, G, Budker, V and Wolff, JA (1999). High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 10: 1735-1737.
29. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
30. Hirata, A, Maeda, N, Hiuge, A, Hibuse, T, Fujita, K, Okada, T et al. (2009). Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 84: 164-172.
31. Hara, A and Radin, NS (1978). Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem 90: 420-426.